Novel anti‑hepatitis B virus flavonoids sakuranetin and velutin from Rhus retinorrhoea

• Published in: Molecular medicine reports Vol. 28; no. 3
• Main Authors: Ahmed, Sarfaraz, Parvez, Mohammad K, Al-Dosari, Mohammed S, Abdelwahid, Mazin A S, Alhowiriny, Tawfeq A, Al-Rehaily, Adnan J
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.09.2023; Spandidos Publications UK Ltd
• Subjects: Adefovir dipivoxil; Antiviral agents; Bioflavonoids; Cytotoxicity; Dichloromethane; Disease resistance; Drug dosages; Drug resistance; Drug therapy; Enzyme-linked immunosorbent assay; Flavones; Flavonoids; Health aspects; Hepatitis B; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus; Identification and classification; Isoflavones; Laboratories; Lamivudine; Ligands; NMR; Nuclear magnetic resonance; Nucleoside analogs; Pharmaceutical industry; Pharmaceutical research; Phytochemicals; Proteins; Quercetin; Software; Viral proteins; Saudi Arabia; Germany; anti‑HBV; velutin; Rhus retinorrhoea; flavonoids; sakuranetin; hepatitis B virus
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.2023.13063

Drug‑resistance in hepatitis B virus (HBV), especially due to prolonged treatment with nucleoside analogs, such as lamivudine (LAM), remains a clinical challenge. Alternatively, several plant products and isolated phytochemicals have been used as promising anti‑HBV therapeutics with no sign of resistance. Among all known species, , and have been widely studied for their anti‑HBV efficacy, however, the effects of have not been previously investigated. The current study reported the isolation of two flavonoids, namely sakuranetin (SEK) and velutin (VEL), from the dichloromethane fraction of aerial parts using chromatography and spectral analyses. The two flavonoids (6.25‑50 µg/ml) were pre‑tested for non‑hepatocytotoxicity using an MTT assay and their dose‑ and time‑dependent inhibitory activities against HBV [hepatitis B surface antigen (HBsAg) and hepatitis B 'e' antigen (HBeAg)] in cultured HepG2.2.15 cells were assessed by ELISA. SEK and VEL at the selected doses (12.5 µg/ml) significantly inhibited HBsAg by ~58.8 and ~56.4%, respectively, and HBeAg by ~55.5 and ~52.4%, respectively, on day 5. The reference drugs LAM and quercetin (anti‑HBV flavonoids), suppressed the production of HBsAg/HBeAg by ~86.4/~64 and ~84.5/~62%, respectively. Furthermore, molecular docking of the flavonoids with HBV polymerase and capsid proteins revealed the formation of stable complexes with good docking energies, thus supporting their structure‑based antiviral mechanism. In conclusion, the present study was the first to demonstrate the anti‑HBV therapeutic activities of SEK and VEL isolated from .